Genomic Vision’s DNA Analysis Technology Singled out in a Study Published by Nature
10 Mars 2016 - 7:13PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics company specializing in the development of
diagnostic tests for genetic diseases and cancers based on
molecular combing technology, announces the publication of
encouraging results regarding its technology in Nature review’s
Scientific Reports: “Molecular Combing of Single DNA
Molecules on the 10 Megabase Scale”. The results of this study
confirm its substantial potential for research into the human
genome and open the way for new applications for molecular
combing.
Published by researchers from the Rockefeller Institute,
Princeton University, Nobel Prize winner Sir Paul M. Nurse from the
Francis Crick Institute and Aaron Bensimon, Co-founder and Chairman
of Genomic Vision, this study highlights molecular combing’s
considerable potential as a research and discovery tool. Having
become a mainstay in the investigation of DNA replication,
molecular combing would now make it possible to analyze larger DNA
fragments, or even entire chromosomes, of up to 12 Mb in human
cells: a significant breakthrough for studying the human
genome.
Discovered in 1998 by Aaron Bensimon, Doctor of Molecular
Biology, former Head of the Genome Stability Unit at the Pasteur
Institute in Paris, “molecular combing” brings an innovative
approach to DNA analysis. Based on this technology, the tests
developed by Genomic Vision make it possible, in an accurate and
targeted manner, to detect complex genetic anomalies responsible
for hereditary diseases and cancers thanks to a panoramic view of
entire DNA molecules.
“The results of the study published by Nature confirm the power
of the approach based on molecular combing in studying DNA
replication, and thus validate Genomic Vision’s ongoing efforts to
provide the most efficient solutions for analyzing the genome’s
structure and dynamics, as well as the most innovative applications
for research,” comments Aaron Bensimon, Co-founder and President of
Genomic Vision.
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company that specializes in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that initially target breast and colon cancers.
Since 2013, the Company has marketed the CombHelix FSHD test for
identifying facioscapulohumeral dystrophy (FSHD), a myopathy that
is difficult to detect. It is marketed in the United States through
a strategic alliance with Quest Diagnostics, the American leader in
diagnostic laboratory tests, and in France directly by the Company.
Genomic Vision has been listed on Compartment C of Euronext Paris
since April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology significantly improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched over glass slides, as if "combed", and uniformly aligned
over the entire surface. It is then possible to identify genetic
anomalies by locating specific genes or sequences in the patient's
genome using genetic markers, a technique developed by Genomic
Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable
and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160310006293/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorKalimaRelations
PresseEstelle Reine-AdélaïdeFlorence Calba+33 6 17 72 74 73 / +33 1
44 90 82 54era@kalima-rp.frorLHAInvestor Relations USAnne
Marie Fields, SVP,
212-838-3777afields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh, +33 1 44
71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024